21st Aug 2018 09:45
LONDON (Alliance News) - Vectura Group PLC said Tuesday that it received positive results form two paediatric studies of its VR647 inhalation system to manage asthma.
The two studies, a pharmacokinetic and methodology one, suggested that the system "may reduce delivery times and potentially reduce steroid dose," in children with asthma compared with marketed nebulised treatments.
"The trials investigated children across different age settings, and results from both studies provide high confidence in the programme, supporting the progression of VR647 to a Phase III programme," the company said.
Executive Vice President and Chief Medical Officer Gonzalo de Miquel said: "There are very few approved treatment options for children under five years of age. The results of these studies support Vectura's confidence in our wholly-owned VR647 product as a more convenient treatment option for children.
"This product has the potential to reduce treatment times and the steroid burden for this patient population, without compromising exposure or safety."
Vectura shares were trading up 1.2% at 79.00 pence each on Tuesday morning.
Related Shares:
VEC.L